PMID- 17827730
OWN - NLM
STAT- MEDLINE
DCOM- 20071012
LR  - 20190720
IS  - 0918-6158 (Print)
IS  - 0918-6158 (Linking)
VI  - 30
IP  - 9
DP  - 2007 Sep
TI  - Effects of manganese complexes of curcumin and diacetylcurcumin on kainic 
      acid-induced neurotoxic responses in the rat hippocampus.
PG  - 1732-9
AB  - This study aimed to investigate the mechanism underlying the protective effects 
      of manganese complexes of curcumin (Cp-Mn) and diacetylcurcumin (DiAc-Cp-Mn) on 
      kainic acid (KA)-induced excitotoxicity in the rat hippocampus. Systemic 
      injection of KA (10 mg/kg, i.p.) caused seizures and increased the expression of 
      neurotoxic markers, immediate early genes [c-jun, cyclooxygenase 2 (COX-2), 
      brain-derived neurotrophic factor (BDNF), and heat shock protein 70 (hsp70)] and 
      a delayed response gene [inducible nitric oxide synthase (iNOS)], which were 
      measured at 6 and 72 h after KA injection, respectively, in the hippocampus. 
      Pretreatment with Cp-Mn (50 mg/kg, i.p.) and DiAc-Cp-Mn (50 mg/kg, i.p.) but not 
      with curcumin (50 mg/kg, i.p.) delayed the onset of KA-induced seizure without 
      affecting the seizure score. KA injection induced c-Fos immunoreactivity in DG, 
      CA1, and CA3 hippocampal regions, the expression of which peaked at 6 h after 
      injection. Cp-Mn and DiAc-Cp-Mn treatment significantly decreased c-Fos 
      expression elicited by KA. Moreover, Cp-Mn and DiAc-Cp-Mn administration 
      suppressed the KA-induced expression of c-jun, COX-2, BDNF, and iNOS mRNA, 
      whereas curcumin attenuated only iNOS mRNA expression. No compounds tested had an 
      effect on KA-induced hsp70 expression. It is therefore likely that in addition to 
      radical scavenging and SOD-like activities, the suppression of potential neuronal 
      injury marker expression by Cp-Mn and DiAc-Cp-Mn, contributes to the 
      neuroprotective activities of these compounds, which are superior to those of 
      curcumin, on KA-induced excitotoxicity in the hippocampus. These results suggest 
      the beneficial effects of Cp-Mn, and DiAc-Cp-Mn on the treatment of 
      excitotoxicity-induced neurodegenerative diseases.
FAU - Sumanont, Yaowared
AU  - Sumanont Y
AD  - Division of Medicinal Pharmacology, Institute of Natural Medicine, University of 
      Toyama, Toyama, Japan.
FAU - Murakami, Yukihisa
AU  - Murakami Y
FAU - Tohda, Michihisa
AU  - Tohda M
FAU - Vajragupta, Opa
AU  - Vajragupta O
FAU - Watanabe, Hiroshi
AU  - Watanabe H
FAU - Matsumoto, Kinzo
AU  - Matsumoto K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Excitatory Amino Acid Agonists)
RN  - 0 (HSP70 Heat-Shock Proteins)
RN  - 0 (Proto-Oncogene Proteins c-fos)
RN  - 42Z2K6ZL8P (Manganese)
RN  - 5PUQ5907YX (diacetylcurcumin)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
RN  - IT942ZTH98 (Curcumin)
RN  - SIV03811UC (Kainic Acid)
SB  - IM
MH  - Animals
MH  - Behavior, Animal/drug effects
MH  - Brain-Derived Neurotrophic Factor/biosynthesis
MH  - Cell Death/drug effects
MH  - Curcumin/*analogs & derivatives/pharmacology
MH  - Cyclooxygenase 2/metabolism
MH  - Excitatory Amino Acid Agonists/*toxicity
MH  - HSP70 Heat-Shock Proteins/biosynthesis
MH  - Hippocampus/*pathology
MH  - Immunohistochemistry
MH  - Kainic Acid/*antagonists & inhibitors/*toxicity
MH  - Male
MH  - Manganese/*pharmacology
MH  - Neurons/drug effects/pathology
MH  - Neurotoxicity Syndromes/*prevention & control
MH  - Nitric Oxide Synthase Type II/biosynthesis
MH  - Proto-Oncogene Proteins c-fos/biosynthesis
MH  - Rats
MH  - Rats, Wistar
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Seizures/chemically induced/prevention & control
EDAT- 2007/09/11 09:00
MHDA- 2007/10/13 09:00
CRDT- 2007/09/11 09:00
PHST- 2007/09/11 09:00 [pubmed]
PHST- 2007/10/13 09:00 [medline]
PHST- 2007/09/11 09:00 [entrez]
AID - JST.JSTAGE/bpb/30.1732 [pii]
AID - 10.1248/bpb.30.1732 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2007 Sep;30(9):1732-9. doi: 10.1248/bpb.30.1732.